Cetuximab or bevacizumab in metastatic colorectal cancer?
Mené sur 592 patients atteints d'un cancer colorectal métastatique sans mutation de l'exon 2 du gène KRAS, cet essai de phase III évalue l'efficacité, du point de vue de la réponse objective, et la toxicité de l'ajout de bevacizumab ou de cetuximab à une chimiothérapie FOLFIRI
n The Lancet Oncology , Volker Heinemann and colleagues report the results of FIRE-3, a randomised phase 3 trial comparing cetuximab with bevacizumab, in combination with fluorouracil, folinic acid, and irinotecan (FOLFIRI), for the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal cancer. The primary endpoint—the proportion of patients with an objective response—and the secondary endpoint of progression-free survival did not significantly differ between treatment gr ..
The Lancet Oncology 2014